ArcticZymes' Novel SAN-HQ enzyme offers gene therapy and vaccine customers a more cost effective and technically superior solution for removing contaminating DNA during the manufacturing process of therapeutic viruses. This represents a critical and challenging step in the manufacturing process where long-established alternative technologies are costlier and technically suboptimal. Cost and technical inefficiencies represent key challenges for the wider adoption of gene therapy. ArcticZymes SAN-HQ allows customers to overcome these hurdles in one part of the complicated workflow in the manufacturing of cGMP grade therapeutic viruses. cGMP (current Good Manufacturing Practices) is relevant when a drug leaves the laboratory and enters into production, where scale, consistent quality and robustness are key requirements.

The undisclosed customer is a leading pioneer in the rapidly growing gene therapy market. Unlike traditional therapeutics, gene therapy provides realistic opportunity to cure devastating childhood genetic diseases and cancers by using viruses to modify DNA within a patient's cells.

Commercial value of individual deals is anticipated to be in the 1-3 MNOK range per annum as customers lock down their large-scale cGMP manufacturing processes. The ability to produce viruses in large-scale is a critical factor to ensure that enough virus can be produced to support clinical trials and approved therapeutics.

"Securing our first supply agreement to support cGMP manufacturing of gene therapy viruses via our novel technologies is a milestone for ArcticZymes. We are excited and privileged that ArcticZymes can play a part in supporting our customers who are pioneering gene therapy solutions to cure devastating and life-threatening diseases." says Jethro Holter, Managing Director ArcticZymes, AS.

For more information, please contact:

CEO Christian Jørgensen, tel +47 47 79 24 57

MD ArcticZymes, Jethro Holter +47 46 85 91 45

About Biotec Pharmacon ASA: 
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics.